
Rafael Holdings, Inc.: A US-based holding company specializing in real estate development and cancer therapeutics.
Rafael Holdings, Inc., founded as a US-based holding company, specializes in real estate development and cancer therapeutics. The company's core mission is to develop novel cancer and immune therapies that address high unmet medical needs. Rafael Holdings is a significant investor in two clinical-stage oncology companies, Cornerstone Pharmaceuticals, Inc., and LipoMedix Pharmaceuticals Ltd. The company also seeks opportunities to invest in, acquire, or in-license additional therapeutic assets.
Notable affiliated people include the leadership teams of Cornerstone Pharmaceuticals and LipoMedix Pharmaceuticals, who are key to advancing the company's oncology initiatives. Rafael Holdings' key achievements include substantial investments in promising cancer therapeutics that have the potential to improve and extend patients' lives. The overall impact of Rafael Holdings lies in its dual focus on real estate and innovative cancer treatments, aiming to make significant contributions to both fields.

Checkpoint Therapeutics
checkpointtx.com

Oncoholdings

Bio-Path Holdings

L.E.A.F. Pharmaceuticals

Raze Therapeutics
razetx.com

Kestrel Therapeutics

Halda Therapeutics
haldatx.com

Rapt Therapeutics
rapt.com

Oncofactor
oncofactor.com

Verastem

Novita Pharmaceuticals
novita-pharm.com

Concarlo Holdings
concarlo.com

Stellanova Therapeutics
stellanovatx.com

Reven Holdings
reven.com

Rainier Therapeutics
Companies similar to Rafael Holdings include Checkpoint Therapeutics, Oncoholdings, Bio-Path Holdings and L.E.A.F. Pharmaceuticals.
Rafael Holdings was founded in 2017.
Rafael Holdings' headquarters is located in Newark, NJ, US.
Rafael Holdings' most recent funding round was for $104.2M (USD) in August 2021.
As of Aug 20, 2021, Rafael Holdings has raised a total of $104.2M (USD).
Rafael Holdings has 13 employees as of Feb 6, 2024.